Table 1 Baseline characteristics of the 31 participants at the pre-infection visit
From: A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy
Characteristic | Median (IQR) or Number (percent) |
|---|---|
Demographics | |
Age (years) | 36 (31 - 38) |
Education (years) | 7 (7 - 8) |
Pregnant | 1 (3.2) |
Hormonal contraceptive method | 7 (22.6) |
OCP | 1 (3.2) |
DMPA | 4 (12.9) |
Norplant | 2 (6.5) |
Risk Behavior | |
Number of partners in the last week | 0 (0 - 1) |
Frequency of intercourse in the last week | 0 (0 - 2) |
Percent condom use in the last weeka | 100 (75 - 100) |
Clinical | |
WHO HIV staging at ART initiation | |
Stage I | 3 (9.7) |
Stage II | 8 (25.8) |
Stage III | 17 (54.8) |
Stage IV | 3 (9.7) |
CD4 lymphocyte count (cells/ml) | |
At start of antiretroviral therapy | 126 (68 - 159) |
Pre-infection visitb | 241 (161 - 292) |
On stavudine, lamivudine, and nevirapinec | 30 (96.7) |
Time since ART initiation (months) | 10.3 (3.6 - 19.0) |
ART adherence in the past month | |
On-time refillsd | 27 (87.1) |
Pill count adherence ≥ 95% | 21 (67.7) |